Sofosbuvir (SOVALDI ® ), a potent, once-daily, orally administered nucleotide analog prodrug
inhibitor of the hepatitis C virus (HCV) NS5B polymerase is approved in the USA, EU, …

Placental efflux transporters such as P-glycoprotein (P-gp) and breast cancer resistance
protein (BCRP) protect the developing fetus from exposure to potentially toxic xenobiotics. …

Elvitegravir is a potent, boosted, once-daily, HIV integrase inhibitor with antiviral activity against
wild-type and drug-resistant strains of HIV. Because elvitegravir is metabolized primarily …

Objective: To assess efficacy and safety of cobicistat versus ritonavir as pharmacoenhancers
for atazanavir when administered with emtricitabine/tenofovir df as initial treatment for HIV-…

Human immunodeficiency virus-infected women (n = 16) received indinavir (800 mg three
times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks …

Objective: Efavirenz (EFV; 600 mg), emtricitabine (FTC; 200 mg) and tenofovir disoproxil
fumarate (TDF; 300 mg) are preferred agents for treatment of HIV-1 infection in adults. This …

Human immunodeficiency virus (HIV)-infected women have reduced exposure [area under
the curve (AUC)] to anti-HIV protease inhibitors [eg, nelfinavir (NFV)] during pregnancy. To …

Objective: Elvitegravir (EVG) is in phase 3 development in combination with ritonavir (RTV)-boosted
protease inhibitors in treatment-experienced, HIV-infected patients. Two studies …

Background Tenofovir alafenamide shows high antiviral efficacy and improved renal and bone
safety compared with tenofovir disoproxil fumarate when used for HIV treatment. Here, we …

Remdesivir (RDV), a single diastereomeric monophosphoramidate prodrug that inhibits
viral RNA polymerases, has potent in vitro antiviral activity against severe acute respiratory …